Document is current
Any future updates will be listed below
-
Authors
Geelen, Inge G.P. https://orcid.org/0000-0001-9470-476X
Gullaksen, Stein-Erik
Ilander, Mette M.
Olssen-Strömberg, Ulla
Mustjoki, Satu
Richter, Johan
Blijlevens, Nicole M.A.
Smit, Willem M.
Gjertsen, Bjorn T.
Gedde-Dahl, Tobias
Markevärn, Berit
Koppes, Malika M.A.
Westerweel, Peter E.
Hjorth-Hansen, Henrik
Janssen, Jeroen J.W.M.
-
Funding
Funding for this research was provided by:
Novartis Pharma
MSD France
- License Information
-
More Information
Article History
Received: 20 June 2022
Accepted: 23 March 2023
First Online: 29 April 2023
Declaration
:
: The Nordic CML Study group is an open academic forum for research on CML, and has performed clinical studies and received financing for this in collaboration with BMS, Novartis, Pfizer and MSD. Both Novartis and MSD supported the present study by provision of study drug free of charge and Novartis gave financial support for study administration. Individual investigators have the following ties to declare: JJWMJ received/receives research support from Novartis and BMS; honoraria for advisory boards from Pfizer and Incyte; speaker’s honoraria from Incyte and Pfizer. He is also the President of the Apps for Care and Science Foundation, that received funding for development of the HematologyApp from Abbvie, Alexion, Amgen, Astellas, Beigene, BMS, Daiichi-Sankyo, Eusapharma, Gilead, Incyte, Janssen pharmaceuticals, Jazz, Novartis, Pfizer, Takeda, Roche and Sanofi. SM has received research support and honoraria from BMS, Novartis and Pfizer.
